Cargando…
Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397905/ https://www.ncbi.nlm.nih.gov/pubmed/28427399 http://dx.doi.org/10.1186/s12916-017-0857-x |
_version_ | 1783230361803685888 |
---|---|
author | Remon, Jordi Besse, Benjamin Soria, Jean-Charles |
author_facet | Remon, Jordi Besse, Benjamin Soria, Jean-Charles |
author_sort | Remon, Jordi |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-5397905 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53979052017-04-21 Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? Remon, Jordi Besse, Benjamin Soria, Jean-Charles BMC Med Erratum BioMed Central 2017-04-20 /pmc/articles/PMC5397905/ /pubmed/28427399 http://dx.doi.org/10.1186/s12916-017-0857-x Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Erratum Remon, Jordi Besse, Benjamin Soria, Jean-Charles Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? |
title | Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? |
title_full | Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? |
title_fullStr | Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? |
title_full_unstemmed | Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? |
title_short | Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? |
title_sort | erratum to: successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? |
topic | Erratum |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397905/ https://www.ncbi.nlm.nih.gov/pubmed/28427399 http://dx.doi.org/10.1186/s12916-017-0857-x |
work_keys_str_mv | AT remonjordi erratumtosuccessesandfailureswhatdidwelearnfromrecentfirstlinetreatmentimmunotherapytrialsinnonsmallcelllungcancer AT bessebenjamin erratumtosuccessesandfailureswhatdidwelearnfromrecentfirstlinetreatmentimmunotherapytrialsinnonsmallcelllungcancer AT soriajeancharles erratumtosuccessesandfailureswhatdidwelearnfromrecentfirstlinetreatmentimmunotherapytrialsinnonsmallcelllungcancer |